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a b s t r a c t
Recent efforts to develop a live attenuated vaccine against Mycobacterium avium subsp. paratuberculosis
(Map), the causative agent of Johne’s disease (JD), revealed relA is important in Map virulence. Deletion of
the relA gene impairs the ability of Map to establish a persistent infection. Analysis of the basis for this
observation revealed infection with a relA deletion mutant (DrelA) elicits development of cytotoxic
CD8 T cells (CTL) with the ability to kill intracellular bacteria. Further analysis of the recall response eli-
cited by DrelA vaccination showed a 35 kDa membrane peptide (MMP) is one of the targets of the
immune response, suggesting it might be possible to develop a peptide-based vaccine based on MMP.
To explore this possibility, ex vivo vaccination studies were conducted with MMP alone and incorporated
into a nanoparticle (NP) vector comprised of poly (D, L-lactide-co-glycolide) and monophosphoryl lipid A
(PLGA/MPLA). As reported, ex vivo vaccination studies showed CD8 CTL were elicited with classic and
monocyte derived dendritic cells (cDC and MoDC) pulsed with MMP alone and incorporated into a
PGLA/MPLA vector. Incorporation of MMP into a NP vector enhanced the ability of CD8 CTL to kill intra-
cellular bacteria. The findings indicate incorporation of MMP into a PGLA/MPLA nanoparticle vector is one
of the possible ways to develop a MMP based vaccine for Johne’s disease.
 2019 Elsevier Ltd. All rights reserved.
1. Introduction
Mycobacterium avium subsp. paratuberculosis (Map) is a zoono-
tic pathogen with a broad host range due to its ability to infect
multiple species including humans [1,2]. Similar to Mycobacterium
tuberculosis and Mycobacterium bovis, exposure leads to develop-
ment of a latent infection under immune control, making it diffi-
cult to detect infected animals during the early stages of
infection. This has led to the inadvertent introduction of Map into
livestock worldwide through movement of latently infected ani-
mals, as clearly illustrated by the emergence of Map in livestock
in the Czech Republic following the fall of Soviet Union in 1989
[3]. The inability to detect animals during the early stages of infec-
tion has emphasized the need to develop a vaccine that induces
sterile immunity to control infection.
Some efficacy has been achieved with the use of killed vaccines,
showing the potential of vaccination as a strategy to clear Map
from livestock [4–8]. However, vaccination with killed vaccines
does not elicit sterile immunity. Efforts are currently underway
to determine if efficacy might be improved through the use of a
live attenuated vaccine [9–13]. As part of an inter-institutional
program to develop attenuated live vaccines, we used site-
directed mutagenesis to evaluate the effect of deletion of specific
genes on the immune response to Map [14]. Initial studies revealed
one of three genes selected for analysis, relA, was unable to estab-
lish a persistent infection in two of the natural hosts, cattle and
goats [15]. Examination at necropsy, revealed the DrelA
mutant could not establish a persistent infection in either species.
https://doi.org/10.1016/j.vaccine.2019.04.040
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Clearance of this mutant was associated with development of an
immune response that impaired the capacity of Map to establish
an infection in vaccinated animals. Flow cytometric (FC) analysis
of the recall response of peripheral blood mononuclear cells
(PBMC) from vaccinated cattle showed vaccination elicited a prolif-
erative response dominated by CD4 and CD8 T cells [15,16].
Two assays were developed to extend these findings. The first
was designed to examine the functional activity of memory CD4
and CD8 T cells present in PBMC from vaccinated steers proliferat-
ing in response to stimulation of blood mononuclear cells (PBMC)
and monocyte derived dendritic cells (MoDC) pulsed with antigen
presenting cells (APC) i.e., conventional denedritic cells (cDC), pre-
sent in peripheral blood, with live DrelA. The second was a viability
assay designed to distinguish live from dead bacteria in Map-
infected macrophage (MU) target cells. Co-incubation of DrelA-
stimulated PBMC from vaccinated cattle, with MU infected target
cells, revealed that stimulation with DrelA elicited the develop-
ment of CD8 cytotoxic T cells with ability to kill intracellular
Map. Further analysis of the recall response revealed an equivalent
response could be elicited with APC pulsed with DrelA or a 35 kDa
membrane peptide (MMP) [17]. This observation suggested that it
might be possible to elicit the same CTL response with MMP alone,
obviating the problems of using an attenuated live vaccine. To
explore this possibility, studies were designed to examine the
immune response to MMP ex vivo. We discovered that CTLs could
be generated ex vivo with MMP alone. This was demonstrated by
modifying the ex vivo functional assay to include two rounds of
stimulation of PBMC with APC pulsed with MMP [17].
The current study was conducted to determine if MMP could be
incorporated into a nano particle vector to develop a method for
vaccine delivery in vivo. A vector comprised of poly (D,L-lactide-
co-glycolide) and monophosphoryl lipid A (PLGA/MPLA) was
examined for its potential use in a peptide-based vaccine for Map
[18]. PGLA is a well characterized polymer that is now commer-
cially available for use in vaccines [19]. MPLA is an endotoxin
derivative used as a vaccine adjuvant that is also commercially
available [20]. It binds specifically to the pro-inflammatory recep-
tor TLR4 present on APC [21]. As reported in the presents study, we
observed that the immune response to MMP was enhanced when
incorporated into the PLGA/MPLA NP.
2. Material and methods
2.1. Animals
Six Holstein steers (12–18 months of age) were obtained from
the Washington State University (WSU) Map-free dairy herd and
used as a source of blood to conduct the studies described herein.
The steers were maintained in an open feed lot by the college Ani-
mal Resource Unit staff. All protocols and procedures were
approved by the WSU Institutional Animal Care and Use Commit-
tee (ASAF 4883).
2.2. Antigen preparation and construction of the PLGA/MPLA vector
The full length MMP, encoded by MAP2121c, was expressed
with the maltose binding protein (MBP) in ClearColi BL21 (DE3)
[22] and purified as previously described [23–25]. We optimized
the coating of nanoparticals with recombinant Map proteins in a
previous study and used those methods herein. [18]. Briefly,
PLGA/MPLAMMP NPs were obtained by using the double emulsion
water-in-oil-in-water (W/O/W) technique. Nine mg of PLGA 75:25
(Mn 25–35 kDa) (Polyscitech) was dissolved in 450 mL of chloro-
form and then 50 mL of 2 mg/mL MPLA (monophosphoryl lipid A)
from S. Minnesota R595-TLR-based adjuvant (InvivoGen) in 1:4
methanol-chloroform mixture was added to the PLGA polymer
solution for loading the PLGA NPs with MPLA at 1% w/v externally.
Next 50 mL MMP protein (20 mg/mL) was added to create a oil-in-
water (O/W) emulsion. For empty PLGA/MPLA NPs, 50 mL PBS buf-
fer was added to the PLGA-MPLA mixture. The resultant was emul-
sified by sonication twice for 30 s each on ice using a Branson
Ultrasonics SonifierTM Cup Horn sonicator at an amplitude of 20%.
The emulsion was added dropwise into 1 mL of 1% poly vinyl alco-
hol (PVA, Mw 31–50 kDa) (Aldrich) while being continuously vor-
texed. This second W/O/W emulsion was then sonicated three
times for 40 s on ice at an amplitude of 40%. Then the emulsion
was added dropwise into 5 mL PVA (1%) and stirred for 4 h to evap-
orate chloroform. Afterward, the mixture was centrifuged at 4 C
for 15 min at 15,000g. The supernatant was discarded. The NPs
were washed three times by centrifugation at 4 C for 15 min at
15,000g in distilled water. The NPs were resuspended by sonication
following pelleting by centrifugation in each wash cycle. After the
final washing the NPs were resuspended in 1 mL of water and
freeze-dried. The morphology of the PLGA NPs was determined
by scanning electron microscopy (SEM). Briefly, dried PLGA/MPLA
preparations with or without MMP were applied onto a pin stub
covered with double-sided carbon tape and then coated with
3.5 nm of platinum/palladium using a Cressington Sputter Coater.
Images were taken using a FEI Quanta 200F SEM (Franceschi
Microscopy and Imaging center, WSU, WA) at 5–10 kV. The PLGA
NPs preparations sizes were then measured using ImageJ software
(NIH, 1.48v). Polydispersibility and zeta potential were assessed by
nanoComposix, Analytical Services in San Diego, CA. A protein
assay kit (Pierce Biotechnology) was used for the quantification
of MMP loading in PLGA NP preparations (%wt). Briefly, 2.5 g of
PLGA NPs were dissolved in 0.2 mL of 0.1 M NaOH solution. After
overnight incubation at 4 C, the protein concentration was mea-
sured using a BCA protein assay kit according to the manufacturer’s
instructions. Sample absorbance was measured at 562 nm by
means of a microplate reader (BioTek, Winooski). Empty PLGA
NPs served as control. Protein encapsulation efficiency (EE), deter-
mine as the ratio of the protein content in the PLGA NPs divided by
the total mass of protein used. A Limulus Amebocyte Lysate (LAL)
kit (Pierce Biotechnology) was used for the determination of the
MPLA LC (% wt) in the NPs. Accordingly, aqueous MPLA solutions
were analyzed with LAL in a plate reader to set up a calibration
curve. MPLA content in the PLGA NPs was calculated by subtracting
the concentration of supernatant-containing MPLA from the
starting concentration of MPLA in the formula. MPLA encapsulation
efficiency was determined by the ratio of the measured MPLA con-
centration in the PLGA NPs to the total concentration of MPLA in
the formula. The properties of NP constructs are listed in
Table 1.
2.3. Bacteria and culture conditions
Cultures of Map wild type strain (K10) were prepared from sin-
gle colonies in Middlebrook 7H9 broth (Difco, BD biosciences, USA)
supplemented with 6.7% para-JEM GS (Trek Diagnostic Systems,
OH), 2 lg/mL mycobactin J (Allied Monitor, MO, USA), and 0.05%
Tween 80 (Sigma-Aldrich Corp.) as previously described [14,15].
The cultures were grown in flasks with occasional shaking at
37 C. When broth cultures reached an OD600 of 0.6–0.8, master
stocks from the upper half of the bacterial suspension were pre-
pared for immediate use in each experiment. Bacterial stocks were
disaggregated by passages through a 26-gauge needle three times
to ensure they were dispersed as a predominant single-cell suspen-
sion. The concentration of bacteria in the final preparation was
estimated based on the final OD600 value [14].
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2.4. Generation of CTL, MoDC and MoMU
As illustrated in the flow diagram (Fig. 1), blood was collected
twice to obtain PBMC to conduct the studies. Whole blood was col-
lected from the jugular vein by venipuncture into bottles contain-
ing acid citrate dextrose (ACD). PBMC were isolated by density
gradient separation using Ficoll-PaqueTM (GE Healthcare Life
Sciences, density 1.077).
Cytotoxic T-lymphocytes (CTL) were generated ex vivo from the
blood of naïve steers as previously described [17]. In brief, blood
was first collected to obtain: (1) monocyte-depleted PBMC
(mdPBMC) that were stimulated with PLGA/MPLA NPs alone and
PLGA/MPLA/MMP NPs processed and presented by circulating den-
dritic cells (cDC), and (2) monocytes that were stimulated with
GM-CSF/IL-4 to generate immature monocyte-derived dendritic
cells (MoDC) for use with MMP and NP constructs in the second
week.
Magnetic microbeads, coated with a cross-reactive anti-human
CD14 mAb, were used to isolate monocytes from PBMC by positive
selection per the manufacturer’s instructions (Miltenyi Biotec Ltd.,
CA), leaving behind the negatively selected mdPBMC containing
cDC [26]. Purity, as assessed by FC with another anti-bovine
CD14 mAb, CAM36A, was 98% [27,28]. To generate the initial
primed T cells, mdPBMC were added to wells of six well culture
plates and cultured in 5 mL (2  106/mL) of complete culture med-
ium (cRPMI) [RPMI-1640 medium with GlutaMAXTM (Life Tech-
nologies, CA, USA) supplemented with 10% calf bovine serum
(CBS), 1 mM b-mercaptoethanol, 100 units/mL of penicillin G, and
100 lg/mL of streptomycin sulfate]. MMP (5 lg/mL), PLGA/MPLA
NPs (25 lg/mL) and PLGA/MPLA-MMP NPs (25 lg/mL) were added
to the cultures. The plates were incubated for 6 days at 37 C, 5%
CO2.
Monocytes from the first blood draw were cultured in 3 mL of
cRPMI in six well culture plates (2  106 per well) in the presence
of a DC growth cocktail containing bovine GM-CSF and IL-4 accord-
ing to the manufacturer’s instructions (Kingfisher Biotech, MN,
USA). On the third day, approximately half of the medium was
replaced with fresh medium containing the cocktail and incubated
an additional three days. On day seven, the MoDC cultures were
washed three times with warm RPMI to remove non adherent
and any dead cells. Three ml of fresh cRPMI was added. Then
preparations of PLGA/MPLA NPs, MMP and PLGA/MPLA-MMP NPs
were added as described above. The Ag-pulsed MoDC culture
plates were centrifuged at 700g for five min prior to incubation
at 37 C with 5% CO2. Following 3 h incubation, the excess of the
Ag preparations was removed by washing three times with RPMI.
The primed mdPBMC were collected and subjected to density
gradient centrifugation to remove dead cells, suspended in fresh
cRPMI and added to their respective autologous Ag- pulsed MoDC
(2  106/mL in 5 mL of cRPMI) and cultured for an additional
6 days for the second round of Ag stimulation. Following collection,
one set of cultures was used to phenotype the cells by FC. The sec-
ond set was used to determine their functional activity using the
CTL and bacterium viability assays as described in the following
paragraph.
To generate MoMU for use as target cells, fresh PBMC, prepared
from the second blood draw, were re-suspended in cRPMI, placed
in 150 mm tissue culture plates and incubated overnight to allow
adherence of monocytes as previously described [16,29]. Following
removal of the majority of the non-adherent cells, the adherent
cells were cultured for 4 days. For use, the differentiated MoMU
were brought into suspension by incubating them on ice in the
presence of EDTA in PBS (4 mL EDTA [250 mM stock in H2O],
5 mL CBS, 91 mL PBS). The cells were washed by centrifugation
and re-suspended in cRPMI, counted and then seeded into wells
of 6 well plates (2  106/well). After an additional 2 days of culture,
the MoMU cultures were washed three times with warm RPMI
without antibiotics to remove any non-adherent and dead cells,
leaving uniform lawns of cells. Fresh cRPMI with no antibiotics
was added to each well to prepare the cell preparations for use
in the viability assay.
2.5. Bacterium viability assay
The bacterium viability assay was used as previously described
(cite here) to compare the extent of intracellular killing of Map
mediated by CTLs generated in response to APC pulsed with
MMP alone or MMP incorporated into the PLGA/MPLA NP vector.
In brief, MoMU in antibiotic free cRPMI were infected with Map
K-10 at a multiplicity of infection (MOI) of 10:1. The culture plates
were centrifuged at 700g for five minutes to maximize uptake of
bacteria, then incubated at 37 C, 5% CO2 for 3 h. Extracellular bac-
Fig. 1. Flow diagram for generating effector and target cells for use in the ex vivo
assays. See methods for detail.
Table 1
Properties of PLGA NPs constructs used in this study.
Formulation Hydrodynamic diameter (nm) Zeta Potential (mV) Polydispersity Index Protein EE (%) MPLA EE (%)
PLGA 431 SD ± 162 14.8 0.141 – –
PLGA/MPLA 400 SD ± 125 8.58 0.947 – 94.8
PLGA/MPLA/MMP 864 SD ± 708.8 23.0 0.67 93.21 93.21
EE = encapsulation efficiency, PLGA = poly (lactic-co-glycolic acid), MPLA = monophosphoryl Lipid, MMP = MAP recombinant peptide.
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teria were removed by washing 5 times with warm RPMI with no
antibiotics. MdPBMC (Ag-primed or unprimed) were added to the
cultures of infected MoMU. Two wells were used as controls, with-
out addition of mdPBMC. All wells of mdPBMC/infected MoMU co-
cultures and infected MoMU control cultures were incubated for
24 h, except cells in one control well that were lysed immediately
following infection with Map using 0.01% saponin in H2O. The pel-
lets were re-suspended in 400 lL of H2O in 1.5 mL translucent
Eppendorf tubes and stored at  20 C for later treatment. At the
end of incubation time, cells (including non-adherent and adher-
ent) in all cultures were lysed and stored as described.
One mL of 20 mM propidium monoazide (PMA) working stock
solution was added to each of 400 mL of the previously prepared
cell lysates. The tubes were incubated for five minutes in the dark
at room temperature using a tube rotator followed by a 5 min of
light exposure using a halogen lamp with a 650 W bulb as
described [17]. The cell pellets were obtained by centrifugation
at 10 000g for five minutes.
In addition to the PMA-treated cell lysates, a set of controls
were prepared for use as reference points when extrapolating the
level of Map killing mediated by Ag specific effector T cells. This
set of controls was made to contain Map mixed in five ratios,
100% live, 75% live/25% killed, 50%live/50% killed, 25% live/75%
killed, and 100% killed. Aliquots of each preparation were added
to the MoMU cultures at MOI of ten respectively and incubated
for three h. The controls were treated with PMA as described [17].
DNA extraction from all PMA-treated tubes, including the
mixed live/dead Map controls, was performed in duplicate accord-
ing to the protocol for Gram-positive bacteria using DNeasy Blood
and Tissue kit (Qiagen, USA) following enzymatic lysis to facilitate
breakdown of theMap cell wall as described by Park et al. [30]. The
TaqMan Quantitative Real-Time PCR, targeting the single copy F57
gene specific for Map (F57 qRT-PCR) was used to determine the
extent of intracellular Map killing relative to the controls based
on the mean cycle threshold (CT) as described by Kralik et al.
[31] and Abdellrazeq et al. [17]. The reaction was performed
according to Schönenbrücher et al. [32] using a StepOnePlus
Real-Time PCR machine (Applied Biosystems, CA). Map gDNA pre-
pared from pure culture was used to generate a standard curve
with the F57 probe, made with 8 dilutions starting with 4  107
copies down to 4 copies. The total reaction volume was 25 lL
including 5 lL of the DNA sample. The reactions were run for 40
cycles. The qRT-PCR conditions and sequences for primer and
probe were the same as previously described [30]. The results were
analyzed using StepOne Software v2.1 (Applied Biosystems, CA).
2.6. Flow cytometric analysis of the recall response
At the times indicated in the flow diagram (Fig. 1), a full set of
mdPBMC (with and without Ags stimulation) were processed for
FC analysis as previously described [17]. In brief, cells were sub-
jected to density gradient centrifugation, washed once in PBS/
ACD then re-suspended in serum-free RPMI and counted. Cells
were distributed in a 96 well polystyrene V-shape bottom micro-
plates (106 cells/well). Combinations of mAbs (Table 2), obtained
from the WSU Monoclonal Antibody Center, were used to label
cells. Data were collected on a FACSsort (BD Immunocytometry
systems, San Jose CA) equipped with a Cell Quest software operat-
ing system or on a modified FACS Calibur DxP8 Analyzer (Cytek
Biosciences, Inc. Fremont, CA) equipped with a Flow Jo Analysis
software operating system. FCS Express software (DeNovo Soft-
ware, Glendale, CA) was used for data analysis. The gating strategy
used to collect the data is shown in Fig. 2. The flow cytometers
were set to collect a minimum of 5  104 events. At the time of
data analysis, FSC versus the memory marker (CD45R0) was used
to determine the frequency of activated memory CD4+ and CD8+
T cells at the initiation of culture and following the first and second
rounds of Ag stimulation.
2.7. Statistical analysis
Data were imported into SAS software (SAS for Windows ver-
sion 9.3 and JMP version 12.0.1; SAS Institute Inc., Cary, NC) for sta-
tistical analysis and graphical presentation (means and standard
deviations). A hierarchical mixed model (the generalized linear
mixed model, or GLIMMIX, procedure) was used to analyze the
effects of two stimulants (four levels defined by the absence, pres-
ence or combined presence of MMP and PLGA/MPLA NPs) on
in vitro activation (proportional) of two types of T-cells (CD4+ or
CD8+). The model was based on a binomial response distribution
and Kenward-Roger degrees of freedom approximation, and resid-
ual error was treated as a random effect defined by subjects (T-cell
type nested within blood-donor steers) and unstructured covari-
ance matrix. A mixed model (GLIMMIX procedure) was also used
to analyze the effects of in vitro CTL stimulation on macrophage
intracellular MAP killing (estimated by CT). The model was based
on a Gaussian response distribution and Kenward-Roger degrees
of freedom approximation, and residual error was treated as a ran-
dom effect defined by subjects (blood-donor steers) and simple
diagonal (variance component) covariance matrix structure. All
post-hoc comparisons of simple effects (least squares means) were
adjusted for multiple comparisons using the method of Holm-
Tukey (overall a = 0.05).
3. Results
Following our previous demonstration that comparable CD8 T
cell responses could be elicited with either DrelA or MMP pro-
cessed and presented ex vivo by APC [17], studies were conducted
to validate the response to MMP and explore the potential of a NP
vector for testing MMP as a peptide-based vaccine. Preliminary
experiments showed NP comprised of PGLA and MPLA could be
prepared in a size range that is readily taken up by MoMU with
no deleterious effects on viability. Further experiments demon-
Table 2
MAbs used in the present study.
mAb Isotype Specificity/Source Fluorochrome Labeling
CAM36A IgG1 CD14 WSUMACa Alexa Fluor 647 Indirect
CAM66A IgM CD14 WSUMACa PE Indirect
209MD26A IgG2a CD209 WSUMACa PE CY5.5 Indirect
ILA11A IgG2a CD4 WSUMACa PE CY5.5 Indirect
CACT138A IgG1 CD4 WSUMACa Alexa Fluor 647 Indirect
7C2B IgG2a CD8 WSUMACa PE CY5.5 Indirect
CACT80C IgG1 CD8 WSUMACa Alexa Fluor 647 Indirect
ILA116A IgG3 CD45R0 WSUMACa Alexa Fluor 488; PE Indirect
a WSUMAC =Washington State University Monoclonal Antibody Center.
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strated candidateMap-derived peptides could be incorporated into
the NP with high efficiency [18]. As part of the overall study design,
cultures of mdPBMC were prepared with MMP alone and incorpo-
rated into the PLGA/MPLA NP. PLGA/MPLA NP alone was also
included as a control to determine if MPLA alone had any effect
on the functional activity of mdPBMC.
As shown in Fig. 3A and similar to results obtained in our pre-
vious studies [17], two rounds of stimulation of APC with MMP
alone elicited robust CD4 and CD8 CTL proliferative responses
(P < 0.0001, each). Stimulation with PLGA/MPLA NP alone also eli-
cited a proliferative response in both CD4 and CD8 T cells
(P < 0.0001, each) but with no CTL activity, as observed with
infected macrophages incubated with unstimulated mdPBMC
(P = 0.2892; Fig. 4. While a significant difference was not detected
between the proliferative responses elicited by MMP alone and
MMP incorporated into the PLGA/MPLA NP (CD4 T cells,
P = 0.6931; CD8 T cells, P = 0.9812; Fig. 3B), there was a difference
in killing activity: the CTL response elicited in mdPBMC stimulated
with MoDC pulsed with PLGA/MPLA-MMP NP (Compare the red
square MMP in the NP vector with the yellow square MMP alone
in Fig. 4A) was significantly greater than the response to MMP
alone (P < 0.0001; yellow square in Fig. 4A).
4. Discussion
Demonstrating the potential efficacy of experimental vaccines
before testing in the field has been a major challenge because
methods available for fully evaluating the immune response to
vaccines have been limited for Map as well as other pathogens.
In the course of our studies on the immunopathogenesis of JD,
we have been able to overcome some of the difficulties encoun-
tered in analysis of the immune response to Map using the natural
host and development of methods for testing the potential efficacy
of candidate vaccines ex vivo. With the use of selective gating dur-
ing flow cytometry, it is possible to isolate CD4 and CD8 memory T
cells proliferating in response to Ags processed and presented by
cDC in blood or MoDC ex vivo. This has facilitated analysis of sig-
naling through APC that drives T cell differentiation during the pri-
mary immune response of naïve T cells and during the recall
response of T cells, ex vivo or in vivo, with T cells from animals
immunized with Ags of interest. Likewise, it allowed for the anal-
ysis of the effector activity of T cells proliferating in response to
Ag stimulation. The adaptation of site directed mutagenesis
allowed for selection of specific genes for deletion to determine
the effect of deletion on the capacity of the mutant to establish a
persistent infection [14]. Adaptation of a propidium-based viability
assay to distinguish live from dead bacteria in a mixed population
of live and dead bacteria obviated problems with culturing this
slow growing pathogen to assess the activity of cytotoxic T cell
activity against intracellular bacteria [17,31].
When we selected genes for analysis of the effect of gene dele-
tion on survival in vivo, we were particularly interested in relA, a
global regulator of multiple gene functions in bacteria [33]. Studies
in mouse models demonstrated deletion greatly reduced survival
in vivo, indicating deletion might in some way alter the immune
response to Map [34,35]. This proved to be a correct assumption.
Deletion of Map resulted in loss of the ability to establish a persis-
tent infection. RelA appears to be the Achilles’ heel of mycobacte-
rial pathogens. Comparative studies are needed with wild type
Map to identify the metabolic products associated with dysregulat-
ing the immune response that are not expressed when relA is
deleted. What was revealed in our studies is that, in absence of
the immunomodulatory products regulated by relA, it is possible
for a protective immune response to develop against Map. Analysis
of the recall response ex vivo demonstrated, inability of Map to
establish a persistent infection, was associated with the develop-
ment of cytotoxic T cells with the ability to kill intracellular bacte-
ria. The immune response to the DrelA mutant may include a
response to multiple bacterial products that differ from the
response elicited by wild type Map. Thus any of the products could
be involved in eliciting a CTL response. Based on previous studies,
we selected MMP as a start for dissecting the immune response to
DrelA. Initial studies had shown MMP is a virulence protein that
enhances invasion of epithelial cells in the bovine intestine [36].
Increased levels of this protein were present under conditions that
mimic the intestinal environment and, antibodies against this pro-
tein significantly inhibited cell invasion. The protein exists as part
of a membrane complex containing other proteins including a cys-
teine desulfurase [37]. A strong antibody response is elicited early
in the course of natural infection with Map [38]. As reported here,
further analysis has now revealed the immune response also
includes development of CTL with the ability to kill intracellular
bacteria [17].
As a further step in exploring the potential of developing a
peptide-based vaccine with MMP, studies were conducted to
determine the potential of a nano particle vector to deliver the vac-
cine in vivo. We chose to use a well characterized NP, PLGA, to ini-
tiate the studies and includedMPLA as a stimulant to target the use
of CTLA-4 for Ag uptake [18]. The use of PLGA/MPLA alone, as one
of the controls, showed it did have a stimulatory effect but the pro-
liferating cells did not develop any CTL activity against Map. Con-
sistent with studies with DrelA and MMP alone, APC pulsed with
PLGA/MPLA-MMP NP elicited a proliferative response equivalent
to stimulation with MMP alone that included both CD4 and CD8
T cells. Although there was no detectable difference in the prolifer-
ative response, there was an increase in the CTL activity in
mdPBMC stimulated with APC pulsed with MMP incorporated into
a NP vector.
The ability to study the functional activity of CD4 and CD8 T
cells proliferating in response to stimulation with APC pulsed with
Ags ex vivo has afforded increased opportunities to evaluate the
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Fig. 2. Flow cytometric assay for phenotyping the effector T cell response to Ag-
pulsed bDC/MoDC. (A) The gating strategy used to first identify the small
lymphocytes (G1, color coded red) and large activated lymphocytes (G2, color
coded blue) by forward scatter (FSC) and side scatter (SSC). (B) A third gate (G3) was
placed on single cells using a pulse geometry gate (FSC-H vs FSC-W) to eliminate
doublets. A fourth gate (G4) was placed on CD4 and CD8 T cells (CD4 cells in this
illustration) to isolate activated cells for analysis. Using FSC vs CD45R0 (a memory
marker) shows activated memory cells responded to Ag stimulation (upper right
quadrant). Only the activated memory cells were considered for statistical analysis.
(For interpretation of the references to color in this figure legend, the reader is
referred to the web version of this article.)
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efficacy of candidate vaccines before testing in vivo. Use of the
methods in the study of the immune response to Map has allowed
us to follow up studies on a relA deletion mutant and show one of
the targets of the immune response, MMP, is a good candidate for
the development of a peptide-based vaccine for JD. It is not clear at
this time, what the best vector should be to obtain an efficacious
(A)
C
D
8
C
D
4
PLGA/MPLA-MMP  NPsControl
13
10
PLGA/MPLA NPs
49
58 69
88
FS
C
CD45R0
(B)
***
***
***
Fig. 3. The proliferative response of CD4 and CD8 T cells to MMP nanoparticles. (A) Representative FC profiles for CD4 and CD8 T cells cultured in medium alone (control) or
stimulated with either PLGA/MPLA NP alone or PLGA/MPLA-MMP NP. (B) Summary of 6 replications of the FC assay comparing the percentage of activated memory CD4 and
CD8 T cells in controls or in response to two rounds of stimulations with PLGA/MPLA NP, MMP or PLGA/MPLA-MMP NP. Data were imported into SAS software for statistical
analysis and graphical presentation (means and standard deviations). See methods for detail. No proliferative response was observed in both CD4 and CD8 T cells in control
cultures. MMP alone elicited a robust CD4 and CD8 proliferative response (P < 0.0001, each). PLGA/MPLA NP alone also elicited a proliferative response in both CD4 and CD8 T
cells (P < 0.0001, each). No significant difference was detected between the proliferative responses elicited by MMP alone or MMP incorporated into the PLGA/MPLA NP (CD4
T cells, P = 0.6931; CD8 T cells, P = 0.9812).
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Fig. 4. CTL kill Map in infected MoMU. (A) Standard curve of the TaqMan F57 qRT-PCR. Five blue square data points represent Map DNA controls from 2  107 Map mixtures
(live and dead), incubated for 3 h with MoMU and then treated with PMA. CT values represent average of duplicate preparations of DNA. Killing activity for all cell treatments
are represented by CT values and plotted using different colors on the standard curve, which is marked by blue data points. Higher CT values indicate higher intracellular
killing activity and vice-versa. (B) Summary of 6 replications of the viability assay comparing killing activities in all cell treatments based on CT values. Mean and standard
deviation for each treatment effect (n = 6 independent experiments). Data were imported into SAS software for statistical analysis and graphical presentation (means and
standard deviations). See methods for detail. No apparent CTL killing activity in mdPBMC stimulated with MoDC pulsed with PLGA/MPLA NP alone, similar to activity
observed in infected macrophages incubated with unstimulated mdPBMC (P = 0.2892). CTL killing activity elicited in mdPBMC stimulated with MoDC pulsed with PLGA/
MPLA-MMP NP was significantly greater than the response to MMP alone (P < 0.0001). (For interpretation of the references to color in this figure legend, the reader is referred
to the web version of this article.)
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response in vivo. Receptor usage during uptake and processing of
MMP by APC may be essential for driving CTL differentiation.
Uptake of Ags through TLRs may be critical in priming APCs to
drive effector T cell differentiation towards protective and non-
protective immune responses [39]. TLR2 usage has been associated
with activation pathways leading to a non-protective immune
response to Map [40]. TLR4 hasn’t been examined by our group
but data suggest usage might be associated with induction of pro-
tective immunity [41]. In the present study, a nonspecific enhance-
ment of the CD4 and CD8 T cell proliferative response was
observed when MPLA was included in a NP vector. It appears this
nonspecific stimulatory effect did not alter the proliferative
response to MMP when incorporated into a PLGA NP vector. How-
ever, there was an increase in CTL activity. Further studies are now
needed to determine whether there is a modulatory effect of MPLA
on Ag processing and presentation by APC in vivo.
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